What Has Been the Growth of the Cardiac Tissue Engineering Market So Far?
The cardiac tissue engineering market has seen considerable growth due to a variety of factors.
• Recent years have seen an accelerated growth in the market for cardiac tissue engineering. Moving from a base of $0.67 billion in 2024, the market is projected to reach $0.81 billion by 2025, reflecting a compound annual growth rate of 19.7%.
This significant increase throughout the historic period stems from factors such as shortages in organ donors, a rising incidence of cardiovascular diseases, innovation in biomaterials, increased investments in the field of regenerative medicine, a growing demand for personalized medical care, advancement in bioreactor technologies, heightened government support for biomedical research, and an escalated interest in minimally invasive therapeutic techniques.
What Are the Future Growth Projections for the Cardiac Tissue Engineering Template Market?
The cardiac tissue engineering market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the cardiac tissue engineering market is anticipated to witness significant expansion, projected to reach $1.64 billion by 2029, with a compound annual growth rate (CAGR) of 19.4%.
Factors contributing to this growth in the forecasted period include a surge in demand for tailored cardiac treatments, increasing concentration on bioengineered heart tissues, development in regenerative medicine applications, the rise in alliances between biotech companies and academic institutions, escalating investments in preclinical testing platforms, and the growing incidence of chronic heart diseases. Key trends during this forecasted period encompass the incorporation of AI into tissue engineering, advancements in nanotechnology-centric scaffolds, the emergence of biodegradable hydrogels, progress in the precision of 3D bioprinting, the employment of bioreactors for tissue maturation, and gene editing for the enhancement of cardiac cells.
What Are the Critical Driver Fuelling The Cardiac Tissue Engineering Market's Growth?
The growth of the cardiac tissue engineering market is anticipated to be driven by the increasing prevalence of cardiovascular diseases. This interdisciplinary sector is specialized in developing biological or bioartificial structures to repair, transform, or replace damaged heart tissue. Unhealthy lifestyle choices, such as poor diet, lack of physical activity, smoking, and escalating rates of obesity and diabetes, are driving the surge in cardiovascular diseases. Cardiovascular diseases are treated with cardiac tissue engineering by generating biomaterials, cell therapies, and bioengineered tissues to mend or regenerate damaged heart muscle and recover cardiac function. For example, the Centers for Disease Control and Prevention, a US governmental organization, reported in May 2023 that the rate of coronary heart disease in female adults aged 18 and over rose slightly to 3.7% in 2023, up from 3.6% in 2022. Thus, the increasing prevalence of cardiovascular diseases is propelling the growth of the cardiac tissue engineering market.
What Are The Major Segments Within The Global Cardiac Tissue Engineering Market?
The cardiac tissue engineering market covered in this report is segmented –
1) By Product: Heart Valves, Vascular Grafts
2) By Material: Stem Cells, Scaffolds
3) By Application: Myocardial Infarction, Heart Valve Repair Or Replacement, Congenital Heart Disease Treatment, Other Applications
4) By End Users: Hospitals And Clinics, Academic And Research Institutes, Other End Users
Subsegments:
1) By Heart Valves: Bioprosthetic Heart Valves, Mechanical Heart Valves, Tissue-Engineered Heart Valves
2) By Vascular Grafts: Synthetic Vascular Grafts, Biologic Vascular Grafts, Tissue-Engineered Vascular Grafts
Pre-Book The Cardiac Tissue Engineering Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Cardiac Tissue Engineering Market?
Leading firms in the cardiac tissue engineering market are enhancing their technological offerings, such as the development of 3D-engineered muscle tissues, to improve accuracy and efficiency in identifying effective cardiovascular disease treatments. These 3D-engineered muscle tissues are bioengineered constructs that mimic human muscle in structure and function, typically used in drug tests and disease simulations. For example, in July 2022, Curi Bio Inc., a US biotechnology company, introduced the Mantarray platform for analyzing contractility in human-relevant 3D heart and skeletal engineered muscle tissue (EMT). This platform employs sophisticated tissue culture techniques to generate highly functional muscle tissues mirroring natural muscle's mechanical attributes and behaviors, providing a more accurate drug testing model. Its design enhances therapeutic solution development by facilitating the study of muscle contraction, stimulus response, and disease modeling at the cellular level.
Who Are the Key Players In The Cardiac Tissue Engineering Market?
Major companies operating in the cardiac tissue engineering market are:
• Biotronik SE & Co. KG
• Terumo Corporation
• Artivion Inc.
• Tissue Regenix Group plc
• PromoCell GmbH
• Xeltis AG
• Carmat S.A.
• Bioheart Inc.
• Prellis Biologics Inc.
• Cytograft Tissue Engineering Inc.
• Avery Therapeutics Inc.
• Vascudyne Inc.
• Auto Tissue Berlin GmbH
• CorMatrix Cardiovascular Inc.
• Humacyte Inc.
• BioCardia Inc.
• Osiris Therapeutics Inc.
• StemCells Inc.
• ViroMed Co. Ltd.
• Cardio3 Biosciences
What Is The Most Dominant Region In The Cardiac Tissue Engineering Market?
North America was the largest region in the cardiac tissue engineering market in 2024. The regions covered in the cardiac tissue engineering market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
